Juvena Therapeutics | $33,500,000 | (Jan 14, 2026)
bricks.sh | $1,863,303 | (Jan 14, 2026)
Allos | $5,000,000 | (Jan 14, 2026)
Certified by Founder
Lodge
AltPep
start up
United States
- Seattle, Washington
- 26/06/2023
- Series B
- $53,000,000
AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach.
Our lead program aims to identify Alzheimer’s Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.
- Industry Biotechnology
- Website https://www.altpep.com/
- LinkedIn https://www.linkedin.com/company/altpep/
PayMedix | $33,000,000 | (Jan 14, 2026)
WeatherPromise | $12,800,000 | (Jan 14, 2026)
Diffraqtion | $4,200,000 | (Jan 14, 2026)
WithCoverage | $42,000,000 | (Jan 14, 2026)
Nodu | $1,450,000 | (Jan 14, 2026)
Cloudforce | $10,000,000 | (Jan 14, 2026)
Converge Bio | $25,000,000 | (Jan 14, 2026)
JetZero | $175,000,000 | (Jan 14, 2026)
TRYBE | $30,000,000 | (Jan 13, 2026)